RU EN
Get tested

Clinical significance

View the diagrams

What it measures
Membrane proteins with a distinctive N-glycosylation pattern typical of poorly differentiated cells. The level reflects proliferative and metabolic activity of the tumour, not its mass; elevated levels have been described with tumours from 5 mm.
Place in diagnostics
A non-organ-specific signal of accumulating poorly differentiated cells, including when the location of the process is not yet known. Conventional markers work within organ-specific diagnostics: clarification, monitoring, assessment of confirmed disease. The methods complement each other, as do molecular tests.
Accuracy
89–94% sensitivity at stage I–II with 95% specificity (blinded studies at Sechenov University, 489 patients and 141 healthy participants). Sensitivity declines only slightly at later stages.
Spectrum
Accuracy is statistically confirmed for carcinomas of the breast, prostate, lung, ovary, kidney and colorectum. Detection cases are described for most tumours, including choroidal melanoma. Sarcomas are not detected; low-Ki-67 tumours are detected later.
Interpretation
Reference interval: up to and including 5,000 U/mL. Above the interval, the manufacturer recommends repeat testing in 30–60 days; with CRP < 10 mg/L the work-up may start without waiting for the repeat. An isolated elevation is not a diagnosis.
Scale
Competitive assay: luminescence in the order of 10⁶ at ~1,000 U/mL and hundreds above 7,000 U/mL; 4,500 and 5,500 U/mL differ in signal by about two orders of magnitude. Close values are not compared directly.
Levels
In patients with suspected cancer, a large share of tumours show levels above 7,000 U/mL. In a prospective study of patients with CT-suspected lung cancer, 87.5% of early cases were above 5,000 U/mL (92.5% versus apparently healthy controls); early adenocarcinomas are more often up to 7,000, squamous cell carcinomas above 7,000.
Above cut-off in healthy people
Among apparently healthy people — about 3% under 40, 5% at 45–60, 6% over 55.
Inflammation
The marker responds to stem cell division during the immune response, not to cytokines. Chronic inflammatory diseases in remission — elevation in no more than 5% of cases; autoimmune diseases — up to 50% (psoriasis — isolated cases).
Use
Primary detection and annual check-ups, screening programmes, monitoring during and after treatment.
Regulatory status
Laboratory-developed test (LDT) in North America since 2025. Roszdravnadzor registration certificate No. RZN 2020/9880 of 3 April 2020 — the world’s first multi-cancer (MCED) test system for detecting epithelial carcinomas with no restriction on tumour site to be authorised for use by a government authority.

Publications and patents

Articles, conference posters, preprints and patents on CA-62, newest first. Posters and patents are available as PDFs.

DateTypePublicationSummaryLinks
Aug 2026PosterCA-62 and Combined Biomarker Performance in Pulmonary Lesions: Prospective Confirmation
Next Generation Dx Summit 2026
Prospective study at Botkin Hospital, Moscow (May 2025 – April 2026): 267 patients with CT-detected lung lesions and biopsy. CA-62 was above 5,000 U/mL in 85.4% of primary lung cancers and in 87.2% at stage I–II (41 of 47); CEA and CYFRA 21-1 were raised in only 23.4% and 12.8% of early cases.PDF
May 2026PreprintUsing CA-62 Marker in a Pilot Screening Project in Kazakhstan, 2021: Baseline Data and Scenario-Based Modeling of Estimated Specificity
Preprints.org
Baseline data from a pilot screening of 1,214 asymptomatic healthcare workers in Kazakhstan: 7.5% of results above 5,000 U/mL, modelled specificity 92.8–94.8%. Not peer-reviewed.Preprints.org · PDF
Aug 2025PosterBalancing High NPV and Insufficient PPV: Results of a Pilot Cancer Screening Study Using the CA-62 Biomarker, with Applicability to its Commercial Use
Next Generation Dx Summit 2025
Pilot screening of 1,005 employees over 45 with occupational cancer risk: 6.2% of results above 5,000 U/mL. CA-62 flagged all 10 known but untreated cancers; one more stage I endometrial cancer was found within a year. PPV 17.5%; no cancer emerged among the 942 people with a normal result.PDF
May 2025ArticleDiagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection: results of the blind clinical study
Frontiers in Oncology, 2025, 15
Double-blind study of 304 people (141 with NSCLC, 133 healthy, 30 with COPD): CA-62 sensitivity at stage I–II 92% at 95% specificity, AUC 0.973.Publisher page
Aug 2024PosterThe Challenge of Early-stage Cancer Detection
Next Generation Dx Summit 2024
Why early cancer is hard to detect at low prevalence, and how a repeat test raises PPV. Screening of 1,000 employees over 50: NPV 100%, PPV 15.9%; model of PPV gain from a repeat CA-62 after 30–60 days.PDF
Jun 2024Conference abstractCA-62: A new biomarker for the detection of early-stage renal cell carcinoma
ASCO Annual Meeting 2024, J Clin Oncol 42 (16 suppl), abstr. 4526
204 people (68 with early-stage kidney cancer, 136 healthy): CA-62 sensitivity 94.3% at 96% specificity.Publisher page · PDF
May 2024PatentNovel cancer antigen for early cancer detection, methods for its production, isolation and detection
Patent RU 2818471 C2, priority 22 Apr 2020, published 2 May 2024
The CA-62 cancer antigen, a family of 60–85 kDa N-glycoproteins with identical N-glycosylation, and the method for its detection. Patent holder: JVS Diagnostics LLC.FIPS register · PDF
Aug 2023PosterCA-62: A Novel Screening Biomarker for Early Cancer Detection
15th Next Generation Dx Summit, Washington DC, 2023
Double-blind study: 600 samples from patients with breast, prostate, lung, kidney and colorectal cancer and 200 controls. CA-62 sensitivity at stage I–II 86–94% at 97% specificity.PDF
Jun 2023ArticlePractical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results
Consilium Medicum, 2023, 25 (6): 406–414
Review of blinded clinical studies of CA-62 in breast, prostate, colorectal cancer and NSCLC; guidance for physicians on interpreting results.Publisher page
Jun 2023Conference abstractA novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection
ASCO Annual Meeting 2023, J Clin Oncol 41 (16 suppl), abstr. 3038
304 samples: the combination of CA-62, CEA and CYFRA 21-1 detected early NSCLC with 93% sensitivity at 100% specificity.Publisher page
May 2023ArticleClinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection
Frontiers in Oncology, 2023, 13: 1009863
Blinded study of 196 patients (mostly DCIS and stage I–II) and 73 healthy women. CA-62 detected 92% of cancers at 93% specificity, including 100% of DCIS and 97% of stage I.Publisher page
May 2023ArticleDiagnostic significance of CA-62 cancer antigen for early detection and differential diagnosis of non-small cell lung cancer: results of the blind clinical trials
Современная онкология / Journal of Modern Oncology, 2023, 25 (1): 82–90
Double-blind study, 304 samples: CA-62 separated NSCLC from controls better than CEA, CYFRA 21-1 and SCC (AUC 0.981), with about 92% sensitivity at stage I–II.Publisher page
2023ArticlePotential clinical application of the cancer antigen CA-62 for differential diagnosis of prostate cancer and benign prostatic hyperplasia at the elevated prostate-specific antigen
Research and Practical Medicine Journal, 2023, 10 (1): 10–26
Blinded study of 325 men: CA-62 helps distinguish prostate cancer from benign hyperplasia in the PSA “grey zone” of 2.5–10 ng/mL.Publisher page
2022PosterLogistic Regression Using a Combination of CA-62, CA 15-3, and Age for Detecting Early Stages of Breast Cancer in Screening
ISOBM Congress 2022, Slovenia
Logistic regression on CA-62, CA 15-3 and age in 300 breast cancer patients and 141 healthy women: 93.3% sensitivity at 99.3% specificity, AUC 0.988, versus 75% with simple combined cut-offs.PDF
2022ArticleDiagnostic efficacy of the new prospective biomarker’s combination CA 15-3 and CA-62 for early-stage breast cancer detection: Results of the blind prospective-retrospective clinical study
Cancer Biomarkers, 2022, 35 (1): 57–69
Blinded study, 488 samples: the CA 15-3 and CA-62 combination detected 75% of DCIS and stage I breast cancer at 100% specificity.Publisher page
Nov 2020PatentReagent kit for detecting a marker of epithelial carcinomas
Patent RU 2735918 C2, priority 7 Jun 2018, published 10 Nov 2020
Reagent kit for measuring CA-62 in serum, the basis of the registered test system. Patent holder: JVS Diagnostics LLC.FIPS register · PDF
2019ArticleA pilot clinical trial to monitor response to chemotherapy using the CA-62 marker of epithelial carcinomas
Siberian Journal of Oncology, 2019, 18 (5): 18–28
Monthly CA-62 monitoring in 89 patients during chemotherapy: marker dynamics matched RECIST response in about 84% of cases.Publisher page

Reference tools

Interactive CA-62 result reference: where the result sits relative to the reference interval and the repeat-testing interval recommended by the manufacturer.

Open the reference

Questions to the developers and clinical discussion — in the Telegram chat for physicians t.me/EarlyDiagnosisPractice. Partnerships with clinics and requests for materials: info@oncomarker.ru.